Targeted & controlled bone healing

Professor Clemens van Blitterswijk - Chairman

Professor Clemens van Blitterswijk, PhD, has served Kuros Chairman since June 2018 and has been a member of the Kuros board since June 2017.  He is the Department Chair and Professor at MERLN Institute for Technology-Inspired Regenerative Medicine at Maastricht University, The Netherlands. Prof van Blitterswijk has founded nine companies over the years. He is recipient of numerous national and international awards like recently “the most entrepreneurial professor of the Netherlands”. He brings over two decades of entrepreneurial science to the Kuros team. Prof van Blitterswijk has authored and co-authored over 350 scientific papers and is inventor on more than 100 patents. He has published three books as an editor, and contributed to many more as a contributing author. Prof van Blitterswijk is a biologist by training and has a PhD in Medicine from Leiden University, The Netherlands. He is Dutch citizen.

Dr. Scott Bruder

Scott P. Bruder, MD, PhD, is an insightful and energetic healthcare leader with a 25-plus year history of bridging basic science, clinical medicine, and industrial development expertise to deliver innovative, commercially successful products that improve patients’ lives around the world. Experience in medical devices, diagnostics, biotechnology, and life science research tools fortify an expansive analytical skill set for this resilient, poised and influential C-Suite executive. An award-winning scientist and clinician, equally comfortable in the laboratory, at the lectern, in the Boardroom or on Capitol Hill, he delivers impactful results by inspiring multi-disciplinary teams to be collaborative, rigorous and decisive. This seasoned Senior Executive, University Professor, and FDA Advisory Committee Member provides a unique bench-to-bedside perspective on unmet needs, development strategy and the path to commercialization.

Leanna Caron

Leanna Caron is a seasoned executive in bio-pharmaceutical and medical device industries.  Ms. Caron developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management. Most recently she served as Executive Vice President and Chief Commercial Officer for AgNovos Healthcare, a company focused on bone health, where she oversaw all aspects of commercial development, launch, and corporate communications. Prior to this role, Ms. Caron was Vice President and General Manager at Sanofi, overseeing the global commercial operations for Cell Therapy and Regenerative Medicine. She has also held senior positions at Genzyme and Merck in the United States, Canada, and Europe and has led several international teams to successfully launch niche/orphan and block-buster products globally. Ms. Caron has served on the boards of WomenLead and CartiHeal, and currently serves as a strategic advisor to the board of CartiHeal, and is Chairman of the Board and President of Skate Canada. She received her pharmacy degree from the University of Toronto, Canada, and her MBA from Concordia University, Montreal, Canada, and Cornell University, Ithaca/NY, USA. Mrs. Caron is a citizen of Canada.

Jason Hannon

Jason Hannon is currently the Chief Executive Officer and a Director of Mainstay Medical, which is focused  on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain. Mr. Hannon has extensive experience in the healthcare and medical devices industry, particularly related to commercialization of new products, penetration of new markets, product innovation, strategic and financial planning, raising capital, regulatory and clinical management, and the building of a high-performance culture. Mr. Hannon previously served as President and Chief Operating Officer of NuVasive (NASDAQ:NUVA), a medical device company focused on the spine market. He helped grow NuVasive from a small U.S.-centric business with a handful of products into the third largest spine company in the world, operating in over 40 countries. During his 12 years at NuVasive, and prior to becoming COO, Mr. Hannon led the international business, was responsible for business development and strategy, and also served as general counsel. Mr. Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.

Dr. Christian Itin

Christian Itin is a non-executive director.  He previously served as Kuros Chairman of the Board from the completion of the merger of Kuros Biosurgery with Cytos Biotechnology in January 2016 until June 2018. Dr. Itin is CEO and Chairman of Autolus Inc., London, UK, since March 2016 and November 2014, respectively. From November 2012 to January 2016, he served as Chairman and CEO of Cytos Biotechnology. Before joining Cytos, Dr. Itin was President and CEO of Micromet Inc., which was acquired in 2012 by Amgen, Inc. Over a period of 13 years, he served in a number of senior management roles at Micromet, becoming CEO in 2004. Dr. Itin received a diploma in biology and a PhD in cell biology from Basel University, Switzerland. In addition, he performed post-doctoral research at the Biocenter of Basel University, Switzerland, and at Stanford University School of Medicine, Stanford, California, USA. Dr. Itin also serves as non-executive director of Kymab Ltd, Cambridge, UK. Christian Itin is a Swiss citizen and resident of Germany.

Giacomo Di Nepi

Giacomo Di Nepi brings over 30 years’ experience in the industry. Currently, he is CEO of Polyphor Ltd, Allschwil, Switzerland. Before, he was Executive Vice President and General Manager, Europe for InterMune Inc., where he launched Esbriet, an orphan drug, and built from scratch a USD 140 million and 200 people business – until the acquisition of InterMune by Roche for USD 8.3 billion. Previously, Mr. Di Nepi was in senior leadership responsibilities with Takeda and Novartis, where he was member of the Pharma Executive Committee. Prior, he was a Partner with McKinsey. Mr. Di Nepi currently serves on the boards of Geneuro (GNRO.PA) and NTC, a privately held company. He holds a degree in Economics from Bocconi University, Milan, Italy, and an MBA from INSEAD, Fontainebleau, France. Mr. Di Nepi is Italian citizen.

Dr. Gerhard Ries

Gerhard Ries is Managing Partner of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharmaceutical industry and venture capital experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Before founding LifeCare Partners, Gerhard was co-founder and managing partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies. Gerhard’s current board memberships include DiaMedCare, Devis Pharma, Leon Nanodrugs, Leukocare and AOInvest. Dr. Ries holds a MS and a PhD degree in Molecular Biology from the University of Basel, Switzerland, and a MS degree in Biotechnology from the Fachhochschule Weihenstephan, Munich, Germany. Mr. Ries is Swiss and German citizen.

Oliver Walker

Oliver Walker is a finance executive with more than 20 years of experience in international companies, both listed and privately-held, and was active in high growth industries and mature industries alike. Amongst other senior positions he was previously CFO of several leading Life Science companies, including Sivantos (Singapore), Nobel Biocare, Sonova, and Stratec (all Switzerland). His experience covers all aspects of finance including M&A, capital market transactions, treasury, reporting and fundraising. Oliver Walker has an MSC in Business Administration & Economics at the University of Berne.

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Board

Professor Clemens van Blitterswijk
Chairman

Professor Clemens van Blitterswijk, PhD, has served Kuros Chairman since June 2018 and has been a member of the Kuros board since June 2017.  He is the Department Chair and Professor at MERLN Institute for Technology-Inspired Regenerative Medicine at Maastricht University, The Netherlands. Prof van Blitterswijk has founded nine companies over the years. He is recipient of numerous national and international awards like recently “the most entrepreneurial professor of the Netherlands”. He brings over two decades of entrepreneurial science to the Kuros team. Prof van Blitterswijk has authored and co-authored over 350 scientific papers and is inventor on more than 100 patents. He has published three books as an editor, and contributed to many more as a contributing author. Prof van Blitterswijk is a biologist by training and has a PhD in Medicine from Leiden University, The Netherlands. He is Dutch citizen.

Dr. Scott Bruder

Scott P. Bruder, MD, PhD, is an insightful and energetic healthcare leader with a 25-plus year history of bridging basic science, clinical medicine, and industrial development expertise to deliver innovative, commercially successful products that improve patients’ lives around the world. Experience in medical devices, diagnostics, biotechnology, and life science research tools fortify an expansive analytical skill set for this resilient, poised and influential C-Suite executive. An award-winning scientist and clinician, equally comfortable in the laboratory, at the lectern, in the Boardroom or on Capitol Hill, he delivers impactful results by inspiring multi-disciplinary teams to be collaborative, rigorous and decisive. This seasoned Senior Executive, University Professor, and FDA Advisory Committee Member provides a unique bench-to-bedside perspective on unmet needs, development strategy and the path to commercialization.

Leanna Caron

Leanna Caron is a seasoned executive in bio-pharmaceutical and medical device industries.  Ms. Caron developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management. Most recently she served as Executive Vice President and Chief Commercial Officer for AgNovos Healthcare, a company focused on bone health, where she oversaw all aspects of commercial development, launch, and corporate communications. Prior to this role, Ms. Caron was Vice President and General Manager at Sanofi, overseeing the global commercial operations for Cell Therapy and Regenerative Medicine. She has also held senior positions at Genzyme and Merck in the United States, Canada, and Europe and has led several international teams to successfully launch niche/orphan and block-buster products globally. Ms. Caron has served on the boards of WomenLead and CartiHeal, and currently serves as a strategic advisor to the board of CartiHeal, and is Chairman of the Board and President of Skate Canada. She received her pharmacy degree from the University of Toronto, Canada, and her MBA from Concordia University, Montreal, Canada, and Cornell University, Ithaca/NY, USA. Mrs. Caron is a citizen of Canada.

Jason Hannon

Jason Hannon is currently the Chief Executive Officer and a Director of Mainstay Medical, which is focused  on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain. Mr. Hannon has extensive experience in the healthcare and medical devices industry, particularly related to commercialization of new products, penetration of new markets, product innovation, strategic and financial planning, raising capital, regulatory and clinical management, and the building of a high-performance culture. Mr. Hannon previously served as President and Chief Operating Officer of NuVasive (NASDAQ:NUVA), a medical device company focused on the spine market. He helped grow NuVasive from a small U.S.-centric business with a handful of products into the third largest spine company in the world, operating in over 40 countries. During his 12 years at NuVasive, and prior to becoming COO, Mr. Hannon led the international business, was responsible for business development and strategy, and also served as general counsel. Mr. Hannon has a JD degree from Stanford University Law School and a BA degree from the University of California, Berkeley.

Dr. Christian Itin

Christian Itin is a non-executive director.  He previously served as Kuros Chairman of the Board from the completion of the merger of Kuros Biosurgery with Cytos Biotechnology in January 2016 until June 2018. Dr. Itin is CEO and Chairman of Autolus Inc., London, UK, since March 2016 and November 2014, respectively. From November 2012 to January 2016, he served as Chairman and CEO of Cytos Biotechnology. Before joining Cytos, Dr. Itin was President and CEO of Micromet Inc., which was acquired in 2012 by Amgen, Inc. Over a period of 13 years, he served in a number of senior management roles at Micromet, becoming CEO in 2004. Dr. Itin received a diploma in biology and a PhD in cell biology from Basel University, Switzerland. In addition, he performed post-doctoral research at the Biocenter of Basel University, Switzerland, and at Stanford University School of Medicine, Stanford, California, USA. Dr. Itin also serves as non-executive director of Kymab Ltd, Cambridge, UK. Christian Itin is a Swiss citizen and resident of Germany.

Giacomo Di Nepi

Giacomo Di Nepi brings over 30 years’ experience in the industry. Currently, he is CEO of Polyphor Ltd, Allschwil, Switzerland. Before, he was Executive Vice President and General Manager, Europe for InterMune Inc., where he launched Esbriet, an orphan drug, and built from scratch a USD 140 million and 200 people business – until the acquisition of InterMune by Roche for USD 8.3 billion. Previously, Mr. Di Nepi was in senior leadership responsibilities with Takeda and Novartis, where he was member of the Pharma Executive Committee. Prior, he was a Partner with McKinsey. Mr. Di Nepi currently serves on the boards of Geneuro (GNRO.PA) and NTC, a privately held company. He holds a degree in Economics from Bocconi University, Milan, Italy, and an MBA from INSEAD, Fontainebleau, France. Mr. Di Nepi is Italian citizen.

Dr. Gerhard Ries

Gerhard Ries is Managing Partner of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharmaceutical industry and venture capital experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Before founding LifeCare Partners, Gerhard was co-founder and managing partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies. Gerhard’s current board memberships include DiaMedCare, Devis Pharma, Leon Nanodrugs, Leukocare and AOInvest. Dr. Ries holds a MS and a PhD degree in Molecular Biology from the University of Basel, Switzerland, and a MS degree in Biotechnology from the Fachhochschule Weihenstephan, Munich, Germany. Mr. Ries is Swiss and German citizen.

Oliver Walker

Oliver Walker is a finance executive with more than 20 years of experience in international companies, both listed and privately-held, and was active in high growth industries and mature industries alike. Amongst other senior positions he was previously CFO of several leading Life Science companies, including Sivantos (Singapore), Nobel Biocare, Sonova, and Stratec (all Switzerland). His experience covers all aspects of finance including M&A, capital market transactions, treasury, reporting and fundraising. Oliver Walker has an MSC in Business Administration & Economics at the University of Berne.